Kairos Pharma Ltd
KAPA0.939USD
+0.020+2.13%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
15.38MCap. mercado
PérdidaP/E TTM
Más Datos de Kairos Pharma Ltd Compañía
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its products consist of five pre-clinical or clinical-trial stage drug candidates developed by it and designed to target immune response, and two therapeutic agents developed by its Enviro Therapeutics, Inc. (Enviro) subsidiary and designed to increase anti-tumor response in conjunction with cancer therapies by addressing resistance to these agents. Its product portfolio includes a variety of technologies licensed by its Enviro subsidiary and consists of compositions and methods for treating diseases and conditions by targeting CD105 and depleting mitochondrial DNA from the circulation. Its products include KROS 101, 102, 201, 301, 401, ENV 105 and 205.
Información de la empresa
Símbolo de cotizaciónKAPA
Nombre de la empresaKairos Pharma Ltd
Fecha de salida a bolsaSep 16, 2024
Director ejecutivoDr. John S. Yu, M.D.
Número de empleados1
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 16
Dirección2355 Westwood Blvd. #139
CiudadLOS ANGELES
Bolsa de valoresNYSE American Consolidated
PaísUnited States of America
Código postal90064
Teléfono18184045541
Sitio Webhttps://kairospharma.com
Símbolo de cotizaciónKAPA
Fecha de salida a bolsaSep 16, 2024
Director ejecutivoDr. John S. Yu, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
5.34M
--
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
30.12K
--
Mr. Douglas W. (Doug) Samuelson, CPA
Mr. Douglas W. (Doug) Samuelson, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Neil Bhowmick, Ph.D.
Dr. Neil Bhowmick, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ramachandran Murali, Ph.D.
Dr. Ramachandran Murali, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Hyun W. Bae, M.D.
Dr. Hyun W. Bae, M.D.
Independent Director
Independent Director
--
--
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
5.34M
--
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
30.12K
--
Mr. Douglas W. (Doug) Samuelson, CPA
Mr. Douglas W. (Doug) Samuelson, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Neil Bhowmick, Ph.D.
Dr. Neil Bhowmick, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ramachandran Murali, Ph.D.
Dr. Ramachandran Murali, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Hyun W. Bae, M.D.
Dr. Hyun W. Bae, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 27 de jul
Actualizado: dom., 27 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Yu (John S)
26.11%
Armistice Capital LLC
6.86%
Technomedics Management and Systems, Inc
5.74%
Bhowmick (Neil Ph.D.)
5.52%
Murali (Ramachandran Ph.D.)
0.67%
Other
55.09%
Accionistas
Accionistas
Proporción
Yu (John S)
26.11%
Armistice Capital LLC
6.86%
Technomedics Management and Systems, Inc
5.74%
Bhowmick (Neil Ph.D.)
5.52%
Murali (Ramachandran Ph.D.)
0.67%
Other
55.09%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
33.18%
Hedge Fund
6.93%
Corporation
5.74%
Investment Advisor
0.68%
Investment Advisor/Hedge Fund
0.10%
Other
53.37%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
19
9.54M
46.63%
+1.19M
2025Q1
19
10.48M
74.82%
+2.27M
2024Q4
13
9.19M
70.90%
+3.62M
2024Q3
9
8.91M
68.86%
+8.91M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Yu (John S)
5.34M
31.7%
--
--
May 01, 2025
Armistice Capital LLC
1.40M
8.33%
+1.40M
--
Mar 31, 2025
Technomedics Management and Systems, Inc
1.17M
6.97%
--
--
May 01, 2025
Bhowmick (Neil Ph.D.)
1.13M
6.7%
--
--
May 01, 2025
Murali (Ramachandran Ph.D.)
137.52K
0.82%
--
--
May 01, 2025
Samuelson (Doug)
104.89K
0.62%
+1.00
+0.00%
May 01, 2025
Scientech Research LLC
48.20K
0.29%
+48.20K
--
Mar 31, 2025
Bae (Hyun W. M.D.)
44.29K
0.26%
--
--
May 01, 2025
SevenBridge Financial Group, LLC
44.29K
0.26%
+44.29K
--
Mar 31, 2025
Aptus Capital Advisors, LLC
44.29K
0.26%
+44.29K
--
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
